NOXOPHARM-LIMITED
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda® ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease. Based on initial positive results, Noxopharm has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
The relevance of blocking TBK1 is seen as important in two respects: (i) ability to block a dysfunctional immune response to RNA viruses such as coronavirus and influenza virus; (ii) potential to avoid the adverse immune-suppressing effects of standard anti-inflammatory drugs such as prednisone and dexamethasone in potentially slowing viral clearance and increasing the risk of secondary infections.
“The NOXCOVID Phase I clinical trial is highly encouraging for Veyonda in this role as a high proportion of the patients were experiencing elevated inflammation,” said Noxopharm CEO and Managing Director Graham Kelly . “In this trial, no major safety issues were identified and 37 of 38 patients hospitalized with moderate respiratory disease recovered.”
“Based on what is known today, Veyonda’s properties give it the potential to address a gap in our armory of COVID-19 therapeutics,” said Marcel Nold , M.D., professor of pediatric immunology at Monash University and the Hudson Institute and pediatrician at Monash Children’s Hospital. “Patients can self-administer, allowing its use in their own home. Its mechanism of action may enable treatment of moderately ill COVID-19 patients and, importantly, it could also be effective against many other viruses. In Veyonda, Noxopharm has an exciting opportunity at hand.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine storm (septic shock).
Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.
Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LatticeFlow AI Acquires AI Sonar, the Leading AI Discovery Platform, to Enable End-to-End, Secure AI Governance21.1.2026 08:22:00 CET | Press release
The acquisition establishes LatticeFlow AI as the industry’s first evidence-based AI governance solution, securely connecting on-prem AI discovery and evaluation with centralized governance operations LatticeFlow AI, a Swiss deep-tech company leading evidence-based AI governance, today announced during the World Economic Forum (WEF) the acquisition of Dublin-based AI Sonar Ltd, a wholly owned subsidiary of CloudSphere Ltd. AI Sonar’s leading edge AI discovery platform allows enterprises and ISVs to detect shadow AI. AI Sonar’s solution will continue to be offered under its brand name by LatticeFlow AI. With this acquisition, LatticeFlow AI will introduce the industry’s first end-to-end, evidence-based AI governance solution securely connecting on-prem AI discovery and evaluations with centralized SaaS governance operations, and covering GenAI, agentic and traditional AI systems. As part of the acquisition, LatticeFlow AI assumes full ownership of AI Sonar’s platform, intellectual prope
Ramboll and Acutro Form Strategic Alliance to Drive Smarter, More Sustainable Intelligent Buildings21.1.2026 08:13:00 CET | Press release
Ramboll, a global leader in engineering, architecture, and consultancy, has entered into a strategic, collaborative partnership with Acutro, specialists in building performance improvement and predictive, data-led maintenance. The partnership brings together Ramboll’s global engineering expertise and Acutro’s digital building intelligence capabilities, creating synergies that support innovation, learning, and value creation for both organisations and their clients. The collaboration enables Ramboll to explore advanced building intelligence tools that can strengthen its digital design capability, while providing Acutro with the opportunity to apply and evolve its platform across complex, real-world projects. Together, the partners will help clients make more informed decisions about performance, lifecycle value, and operational risk. The multi-year relationship provides Ramboll with access to Acutro’s cloud-native platform, creating opportunities to integrate real-time performance analy
STREAMWIDE Marks Major APAC Milestone with UPCAD Public Safety Deployment in the Philippines21.1.2026 08:00:00 CET | Press release
STREAMWIDE has been selected by UPCAD (Unified Platform for Communication and Dispatch) of the Philippines to power its next generation critical communications platform for first responders integrated with national 911 call centers. Through this collaboration, UPCAD integrates STREAMWIDE’s field proven mission critical technology with the national 911 services, the new solution is designed to ensure uninterrupted, secure, and reliable communication during emergencies, enabling faster response times, improved situational awareness, and enhanced public safety outcomes. By integrating directly with 911 call centers, the platform enables real-time sharing of critical information such as caller location, incident details, and response status with first responders and command teams. Through our API, the platform integrates digital workflow capabilities, allowing information to flow seamlessly into the same system. This enables up-to-date reporting while automatically creating incident workfl
H2SITE Launches Norwegian Subsidiary to Accelerate Ammonia-to-Power and Maritime Decarbonisation21.1.2026 07:00:00 CET | Press release
H2SITE has launched H2SITE Norway AS, a new subsidiary based in Bergen, to enable the future of maritime hydrogen solutions. The company’s presence in Norway reflects its intention to work closer to the maritime and offshore industry and to support the practical deployment of hydrogen-based solutions for vessel decarbonisation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120617713/en/ H2SITE Ammonia Cracking Solution H2SITE is a Spanish scale-up company headquartered in Bilbao, where the core of its technology is designed and manufactured. From its industrial facility in Loiu (Bizkaia), H2SITE produces thousands of palladium-alloy membranes each year, which are integrated into membrane reactor systems enabling efficient conversion of hydrogen carriers back into hydrogen. In the case of ammonia, H2SITE has developed cracking systems capable of delivering high-purity hydrogen that can be supplied directly to fuel cells o
2026 Japan Prize Laureates Announced21.1.2026 06:00:00 CET | Press release
The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. (JST) on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication, and 185 nominations for the field of Life Scie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom